The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
Good morning again HbD,
Indications and potential with regards to Tyk2 and Jak1 have been well documented.
Pleased you have read and given a very credible response.
As you will realise the potential worth here is considerable.
There exists plenty of room here for 1801 to surpass Deucravacitinib in some Indications and Psoriasis being one if them
We must also take into account that very importantly inter leuken 10 that is of great relevance with regards to the auto immune system consists of 4 sub units of which 2 are controlled by Jak1, and 2 are controlled by Tyk2
Also of relevance is the degree of selectivity of Jak1 over Jak2 and Jak3, of which we are from memory 4 or five fold selective over.
If we now take the extremely high purity of our SdC compounds that use our patent protected crystallisation of a compound. ( yes we have had the naysayers claim that this is not new and indeed they are correct) However it has its importance in ensuring top patent protection guarding its manufacture.
The final icing on the cake is the administration via the oral route through capsule formulation which basisicslly removes the possibilities of the compound or part compound passing through the intestinal tract unabsorbed.
Great for dosing precision.
LADMET.
Regards
Regards and have a great day.
Whoops forgot to add
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/
Apologies
A link below to jakis and relevant particularly to our SDC compounds.
A very long read, and a lot longer to understand than those with limited or very limited knowledge which of course cannot be gained overnight.
Those that read and have fully understoodd l welcome comments.
Those that read a bit and and try to find anything to turn into a negative can also reply.
Nothing here in this about finance of course.
I believe we have good people already on this case.
So investors present and future take a read. Read have a rest and read some more.
All the best to the the gents and ladies that will be in Pampisford today. The combined benefit of positive like minded individuals have far greater potential when pulling in the same direction than the sum of their individual counterabilites.
Pampisford the name of the Oz company putting our SDC compound through its paces in phase1 trials
Regards to all invested, but especially the Pampisford meeting crew.
The snakes belly is very quiet at the moment.
I really cringe when some on here state how they should have taken his advice. How right Puma was.
Tell me that if all had taken his advice which basically he was constantly pushing investors to do and also deter new investors.
Where would the company be now? Those that sell up first followed by those that follow further down the line, until you reach those at the end that get nothing.
All the while he is vlaiming to want to help you.
The attitude of that individual does not care for others proven beyond all doubt by the insults hurled at very respected wise posters here.
One especially at PCS1954 with regards to Alzeimers disease
It has its own agenda of that there can be no doubt. Ignorance and arrogance by the bucket load plus a similar bunch of individuals over on the ADVN channel.
It was certainly blown out of the water this morning.
Regards
PCS1954, AndyMkDon, and any other LTH.
Have decent day out tomorrow at Pampisford, I would liked to have attended but work reqyirement does not allow me to take the day off.
Let us know how you get on. You may even bump onto Ratcliffewriter.
Regards and all the best.
Yes Potters,
Aurora+FLT3 very effective but had solubility issues. Problems therefore in manufacturing the compound to be administered intravenously.
I am not sure if they ever considered the oral route as they have undertaken with 737 2801 and 1802.
There exist a multitude of options for incombo therapy with 737. It inhibits via the mutation at P53 checkpoint as we know and whilst in over 50% of cancers, in HGSOC mutations at P53 are around 95.
As a checkpoint inhibitor can only work during mitosis it can prevent new cancer growth but importantly need DNA damaging agents such as chemo by killing cells and causing cell damage.
Resistance to 737 can and and does develop as the cancer then uses a different pathway.
It is here that other inhibitors such as Parpi or more particularly a PD-1 inhibitor especially in combination with a DNA damaging agent ie LDG have very significant effect.
It is very unfortunate for what ever reason that clinical trial has not been utilised to advace this type of therapy for the benefit of patient care
Regards
Section c.
a)the maximum amount deposited and outstanding being not greater than 10% of the market capitalisation of the Company at the time of the deposit.
b) the maximum amount drawn and outstanding being not greater than a 15x multiple to the 10-day and 20-day Average Daily Traded Value of the Company's ordinary shares.
c) maximum amount deposited and outstanding being not greater than £1 million prior to the deposit.
· Future deposits, to the balance of up to £1 million (the "Future Deposits"), may be mutually agreed between the Company and RiverFort.
Damion part of the agreement was that total amount owing with new drawdown does not exceed 10% of market cap.
What we owe at the moment is roughly 10% of our market cap.
Any further renegotisted finance from RF would result in new likely far more damaging outcome than we have at the moment. Effectively they would almost own it. No need do deal.with Sareum go to Riverfort
There is no way RF as l see it lend more in current agreement,
But that is far from the end of the world.
Regards
Bigeasy94
I don't believe they went for a big placing, that maybe a main reason for low low price SP.
Nigh 80 million market cap so to raise 6 million dollars investor will want a bigger slice of the pie.
I would reckon that they would have benefitted raising 100 million with the intention of taking 1801 into phase3.
However, this would not fit into Sareums plan of looking to licence end of phase 1 b.
It would of given finance to 1802 too!
Yes dilution would be heavy but nowhere near the same devastation as we sit at the moment.
Yes pharma are corrupt and l have posted heavily with regards to corrupt pharmas where billions have been paid in fines, GSK being one of them.
Emma Warmsley has not had her pay increased to 13 million dollars a year for doing diddly squat.
Partnership of some sort with up front finance is a good way forward and I would like to think the BoD are working their ar5es off on this one, or along these lines.
Regards
Damion made a very pertinent point of needing 2 million before end of Aussie tax year to enable the 1.6 million in tax credits.
A placing to get 2 million at these current levels plus what RF have they will need circa 20 million shares.
Finance l would have thought would be a cost option being the lesser of 2 evils.
A pharma may raise Sareum the funding but would very much be on the pharmas terms as they hold the ace in their hand.
2 million is not much in the scheme of things and 1801 is worth considerably more than our current market cap.
I take it we are still in communication with interested parties, but for what we have and potential worth on 'top line expected dainty data 2 million is peanuts.
Ideally RF need removing from the equation.
Constantly pouring shares into the market creating excessive supply over demand what appears to be deliberate downward pressure on Sareum SP.
How close are Sareum in these discussions have they progressed?
They require data and very little l feel will be done until that data is delivered in full.
Regards
Just found a little extra regarding tax credits in OZ
30 June 2024
Official end of the fiscal year.
1 July 2024
The Australian Taxation Office begins to process tax returns from the fiscal year just ended.
Regards
Opus!
The same Opus that used to buy bad debt in around 2010 and drive people suicidal with court and bailiff threats.
Not exactly what they preach on their website.
I presume Parker would know all the ins and outs with upsides as well as downsides. It would be interesting to see if he pointed out the downsides.
Regards
Perhaps they could obtain a loan, to take them to phase1b completion.
There will be a ball park figure of what 1801 is worth and rate a pharma will pay.
It will have value end of phase1a data results so why not use this value to access funding?
Excellent chemists but lacking in business acumen.
I trust the BoD are working at pace on this.
Little in the RNS to indicate cash runway.
Regards
Buys and sells nigh the same 300k shares traded so far.
Calling an AGM wil not stop RF selling.
It did occur to me while back if the HNWI's had anything to do with RF?
Remember back at July last year heavy sells around 2 weeks before RF came aboard.
Some suggested it may be Thoth2 that sadly passed away.
I do hope the BoD are working on that alternative means of finance.
As the share price drops so should their salaries by the same ratio haha, that would really be performance related pay.
Onwards and upwards,
Regards
You got me on that one. I have no idea.
I see no reason why there should be a lack of information on this as Sareum has 27.5% financial interest.
Acrivon raised 100 million dollars for discontinued Prexasertib as related to myocarditis.
737 there was not an associated problem.
All very quiet on this front.
Not of benefit to Sareum if they were pinning their hopes on much larger upfront payment.
I would expect update or confirmation here in first week of April. Around 3 months from start to finish to agreement finalisation.
Regards
Hood,
A licencing deal sonny does not involve dilution.
Let me carefully put to you.
A licensing deal consists of an upfront payment, followed by milestone payments.
Please explain where the dilution comes in.